Literature DB >> 26567747

Lymphocytes in Alzheimer's disease pathology: Altered signaling pathways.

Noemí Esteras, Carolina Alquézar, Ana de la Encarnación, Ángeles Martín-Requero1.   

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder marked by progressive impairment of cognitive ability. Patients with AD display neuropathological lesions including plaques, neurofibrillary tangles, and neuronal loss in brain regions linked to cognitive functions. Despite progress in uncovering many of the factors that contribute to the etiology of this disease, the cause of neuronal death is largely unknown. Neuroinflammation seems to play a critical role in the pathogenesis of AD. Inflammatory processes in the brain are mainly mediated by the intrinsic innate immune system consisting of astrocytes and microglial cells, and cytokine, chemokine, and growth factor signaling molecules. However mounting evidence suggest that the Central Nervous System (CNS) is accessible to lymphocytes and monocytes from the blood stream, indicating that there is an intense crosstalk between the immune and the CN systems. On the other hand, some AD-specific brain-derived proteins or metabolites may enter the plasma through a deficient blood-brain barrier, and exert some measurable signaling properties in peripheral cells. The goals of this review are: 1) to explore the evidences of changes in signaling pathways that could mediate both central and peripheral manifestations of AD, and 2) to explore whether changes in immune cells, particularly lymphocytes, could contribute to AD pathogenesis.

Entities:  

Mesh:

Year:  2016        PMID: 26567747     DOI: 10.2174/1567205013666151116124912

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  5 in total

1.  Sex Differences in Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer's Disease Patients.

Authors:  Marta Sochocka; Michał Ochnik; Maciej Sobczyński; Beata Orzechowska; Jerzy Leszek
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-06-16       Impact factor: 4.291

2.  Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.

Authors:  Karol Dowjat; Tatyana Adayev; Urszula Wojda; Katarzyna Brzozowska; Anna Barczak; Tomasz Gabryelewicz; Yu-Wen Hwang
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

3.  Single-cell RNA sequencing reveals B cell-related molecular biomarkers for Alzheimer's disease.

Authors:  Liu-Lin Xiong; Lu-Lu Xue; Ruo-Lan Du; Jia Liu; Chang-Yin Yu; Ting-Hua Wang; Rui-Ze Niu; Li Chen; Jie Chen; Qiao Hu; Ya-Xin Tan; Hui-Fang Shang
Journal:  Exp Mol Med       Date:  2021-12-08       Impact factor: 12.153

4.  TDP-43 Pathology and Prionic Behavior in Human Cellular Models of Alzheimer's Disease Patients.

Authors:  Eva P Cuevas; Alberto Rodríguez-Fernández; Valle Palomo; Ana Martínez; Ángeles Martín-Requero
Journal:  Biomedicines       Date:  2022-02-05

5.  Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment.

Authors:  Loreto Martínez-González; Carmen Rodríguez-Cueto; Diego Cabezudo; Fernando Bartolomé; Pol Andrés-Benito; Isidro Ferrer; Carmen Gil; Ángeles Martín-Requero; Javier Fernández-Ruiz; Ana Martínez; Eva de Lago
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.